Table 2.
Clinical characteristics of PTC patients with non-131I-avid and 131I-avid metastases.
| Clinical Characteristics |
131I-avid (n = 48) |
Non-131I-avid (n = 21) |
p-Value |
|---|---|---|---|
| Age (mean ± SD, years) | 45.2 ± 12.1 | 47.7 ± 18.3 | 0.514 |
| ≥55/<55 | 9 (18.8%)/39 (81.2%) | 6 (28.6%)/15 (71.4%) | 0.363 |
| Gender (male/female) | 16 (33.3%)/32 (66.7%) | 9 (42.9%)/12(57.1%) | 0.449 |
| BMI (mean ± SD, kg/m2) | 23.0 ± 3.0 | 23.3 ± 4.5 | 0.722 |
| Nodular goiter (yes/no) | 27 (56.3%)/21 (43.7%) | 8 (38.1%)/13 (61.9%) | 0.165 |
| Hashimoto’s thyroiditis (yes/no) | 8 (16.7%)/40 (83.3%) | 4 (19.0%)/17 (81.0%) | 0.811 |
| Graves’s disease (yes/no) | 4 (8.3%)/44 (91.7%) | 0 (0.0%)/21 (100.0%) | 0.306 |
| Multifocality (yes/no) | 16 (33.3%)/32 (66.7%) | 8 (38.1%)/13 (61.7%) | 0.702 |
| T stage (T1-T2/T3-T4) | 4 (8.3%)/44 (91.7%) | 1 (4.8%)/20 (95.2%) | 0.553 |
| n stage (N0/N1) | 7 (14.6%)/41 (85.4%) | 1 (4.8%)/20 (95.2%) | 0.420 |
| RAI dose (median, uci) | 100 (100–150) | 100 (100–200) | 0.698 |
PTC: papillary thyroid cancer; SD: standard deviation; BMI: body mass index; RAI: radioiodine.